BB-2121
Drug
Celgene Corporation
Total Payments
$17.7M
Transactions
403
Doctors
51
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $11.5M | 334 | 48 |
| 2018 | $6.2M | 69 | 13 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $17.4M | 89 | 98.4% |
| Consulting Fee | $215,951 | 44 | 1.2% |
| Travel and Lodging | $33,050 | 126 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,588 | 29 | 0.2% |
| Food and Beverage | $5,350 | 115 | 0.0% |
Payments by Type
Research
$17.4M
89 transactions
General
$283,940
314 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| BB2121-MM-001 - PhII Ide-Cel in RRMM | Celgene Corporation | $4.9M | 0 |
| Ph IIB Ide-Cel Multi-Cohort mono RRMM (BB2121-MM-002) | Celgene Corporation | $4.0M | 0 |
| PhII Ide-Cel in RRMM (BB2121-MM-001) | Celgene Corporation | $3.9M | 0 |
| PhIII Ide-Cel vs Triplet RRMM 3L (BB2121-MM-003) | Celgene Corporation | $1.5M | 0 |
| CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma (CRB-401) | Celgene Corporation | $1.1M | 10 |
| CRB-401 - CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma | Celgene Corporation | $679,719 | 10 |
| CRB-401 - CRB-401A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma | Celgene Corporation | $648,039 | 0 |
| CRB-401A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma (CRB-401) | Celgene Corporation | $558,285 | 0 |
| Phase II Multicenter Clinical Trial of anti-B Cell Maturation Antigen Chimeric Antigen Receptor T-cells (bb2121) after Autologous Hematopoietic Cell Transplant for Upfront Treatment of High-Risk Multiple Myeloma (bb2121-CL-MM-BMTCTN-13888) | Celgene Corporation | $116,701 | 0 |
Top Doctors Receiving Payments for BB-2121 — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Hematology & Oncology | Phoenix, AZ | $6,244 | 10 |
| , MD | Hematology & Oncology | Las Vegas, NV | $6,162 | 7 |
| , M.D | Medical Oncology | Phoenix, AZ | $6,156 | 8 |
| , MD PHD | Hematology & Oncology | Williamsville, NY | $5,816 | 10 |
| , M.D | Hematology & Oncology | San Antonio, TX | $5,807 | 8 |
| , MD | Hematology & Oncology | Rochester, NY | $5,536 | 8 |
| , M.D | Student in an Organized Health Care Education/Training Program | Orlando, FL | $5,406 | 10 |
| , MD | Medical Oncology | Wyoming, MI | $5,390 | 4 |
| , M.D | Hematology & Oncology | Rockville, MD | $5,056 | 8 |
| , DO | Medical Oncology | Des Moines, IA | $5,031 | 6 |
| , M.D | Hematology & Oncology | Flint, MI | $4,792 | 7 |
| , MD | Hematology & Oncology | Mesa, AZ | $4,761 | 8 |
| , MD | Hematology & Oncology | Chico, CA | $4,631 | 9 |
| , M.D | Hematology & Oncology | Ocala, FL | $4,448 | 7 |
| , MD | Hematology & Oncology | Federal Way, WA | $4,377 | 7 |
| , MD | Hematology & Oncology | Easton, PA | $4,279 | 5 |
| , MD | Hematology & Oncology | New Hyde Park, NY | $4,269 | 5 |
| , M.D | Family Medicine | Ventura, CA | $3,993 | 8 |
| , MD | Hematology & Oncology | Gettysburg, PA | $3,614 | 6 |
| , MD | Internal Medicine | Yakima, WA | $3,592 | 7 |
| , MD | Hematology & Oncology | Binghamton, NY | $3,032 | 3 |
| , MD | Hematology & Oncology | Philadelphia, PA | $2,025 | 1 |
| , MD | Hematology & Oncology | New York, NY | $2,025 | 1 |
| , MD | Hematology | Boston, MA | $2,025 | 1 |
| , MD | Internal Medicine | Milwaukee, WI | $2,025 | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $17.7M
Product Information
- Type Drug
- Total Payments $17.7M
- Total Doctors 51
- Transactions 403
About BB-2121
BB-2121 is a drug associated with $17.7M in payments to 51 healthcare providers, recorded across 403 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2018 to 2019. In 2019, $11.5M was paid across 334 transactions to 48 doctors.
The most common payment nature for BB-2121 is "Unspecified" ($17.4M, 98.4% of total).
BB-2121 is associated with 9 research studies, including "BB2121-MM-001 - PhII Ide-Cel in RRMM" ($4.9M).